First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Impact ledger

    AstraZeneca PLC (AZN): the developments shaping its investment case

    Follow the evidence affecting AstraZeneca PLC's demand outlook. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.

    Research AstraZeneca PLC · $399/mo

    Test assumptions, examine opportunities, and save your research.

    Material developments

    2026-09-29
    AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung Cancer
    Channel: Direct revenue potential from new drug combination approval, expanding market share in NSCLC.
    Bullish· 3-12m
    2026-09-24 · 6 reports
    Hutchmed to Present Phase III Savolitinib NSCLC Trial Results at ESMO 2026 Congress
    Channel: Positive clinical trial results for a combination therapy involving a key marketed product (osimertinib/Tagrisso), potentially expanding its addressable market and extending its patent life/market exclusivity.
    Bullish· 3-12m
    2026-09-29 · 2 reports
    AstraZeneca files US FDA NDA for savolitinib combo in MET-driven lung cancer
    Channel: Regulatory progress for a novel oncology combination therapy, potentially expanding market share and revenue streams in lung cancer treatment.
    Bullish· 3-12m

    Evidence affecting valuation assumptions

    Each entry names the assumption the evidence touches and how the evidence reads. Direction describes the business mechanism, not a stock-price conclusion.

    DateAssumptionDirectionInterpretation
    2026-08-06share_countBullishStock component of consideration dilutes existing acquirer holders.
    2026-08-06net_debtBullishCash component of consideration is typically debt-funded, raising net debt.
    2026-08-06revenueBullishAcquisition adds target revenue to acquirer P&L on close.

    Event impact log

    22 events mapped to AZN since 2026-08-28. Evidence through 2026-09-29.

    DateEventChannelDirectionHorizonImpact
    2026-09-29AstraZeneca files US FDA NDA for savolitinib combo in MET-driven lung cancerRegulatory progress for a novel oncology combination therapy, potentially expanding market share and revenue streams in lung cancer treatment.Bullish3-12m0.60
    2026-09-29AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung CancerDirect revenue potential from new drug combination approval, expanding market share in NSCLC.Bullish3-12m0.80
    2026-09-29AstraZeneca Submits US NDA for Savolitinib and Tagrisso in MET-Driven Lung CancerDirect regulatory progress for a key oncology asset, potential for future revenue generation.Bullish3-12m0.70
    2026-09-24Hutchmed to Present Phase III Savolitinib NSCLC Trial Results at ESMO 2026 CongressPositive clinical trial results for a combination therapy involving a key marketed product (osimertinib/Tagrisso), potentially expanding its addressable market and extending its patent life/market exclusivity.Bullish3-12m0.60
    2026-09-24Vertex Inaxaplin Phase IIb Cuts Proteinuria in Kidney Disease TrialIncreased competitive pressure in the kidney disease therapeutic area, potentially impacting future market share for existing or pipeline drugs.Bearish3-12m0.30
    2026-09-24HUTCHMED and AstraZeneca Present Phase III Lung Cancer Data at ESMOPositive clinical trial results for a combination therapy involving a key marketed product (osimertinib) and a partnered asset (savolitinib), extending market exclusivity and treatment options.Bullish1-3m0.60
    2026-09-24HUTCHMED and AstraZeneca present Phase III lung cancer data at ESMO 2026Direct positive clinical trial results for a combination therapy involving a key marketed product (osimertinib) and a partner's drug, potentially expanding market opportunities and extending patent life/market exclusivity.Bullish1-3m0.75
    2026-09-24Ionis Reports Positive Phase III Endpoints in ALS and Kidney DiseasePotential indirect competitive pressure or market dynamics shift in kidney disease treatment. While not directly involved in these specific drugs, AZN has a significant presence in renal and rare disease markets.watch3-12m0.30
    2026-09-24HUTCHMED and AstraZeneca to Present Savolitinib Phase III NSCLC Data at ESMODirect impact from positive clinical trial data presentation for a co-developed asset, reinforcing pipeline strength and potential future revenue contribution.Bullish1-3m0.60
    2026-09-24HUTCHMED to Present Phase III Savolitinib Lung Cancer Data at ESMO 2026Positive clinical trial data for a co-developed oncology asset, contributing to pipeline strength and future revenue potential, though impact is diluted by AZN's larger portfolio.Bullish1-3m0.60
    2026-09-21Ionis Plunges Over 40% Following Clinical Setbacks in Pelacarsen and EplontersenSecond-order effect from partnership revenue loss for pelacarsen, though diversified pipeline mitigates overall impact.Bearish3-12m0.20
    2026-09-21Ionis Plunges Over 40% YTD on Late-Stage Setbacks Despite Bullish TargetsIndirect impact through partnership agreements and potential milestone payments or royalty streams from Ionis's ASO assets.watch3-12m0.30
    2026-09-21Ionis slides over 40% year-to-date following late-stage clinical setbacksPartnered drug development. Pelacarsen is a co-development program with AstraZeneca. Setbacks directly impact potential future milestone payments and shared profits.Bearish1-3m0.40
    2026-09-21Ionis Pharmaceuticals faces pipeline pressure after pelacarsen and eplontersen trial setbacksPartnership risk. AstraZeneca is a partner for pelacarsen. Setbacks for this drug could reduce future royalty/milestone payments.Bearish3-12m0.30
    2026-09-21Ionis Pharmaceuticals trades down 40% following late-stage clinical setbacksLoss of potential future milestone payments and royalties from pelacarsen, which was partnered with AstraZeneca. Reputational risk for partnership efficacy.Bearish3-12m0.30
    2026-09-15Summit Therapeutics Inc. Announces Updated HARMONi Data Presented at WCLC 2026Potential increased competition in the EGFR-mutated NSCLC market, where AstraZeneca's Tagrisso (osimertinib) is a dominant therapy. Ivonescimab's data could challenge or complement existing standards of care.mixed3-12m0.30
    2026-08-31HUTCHMED and AstraZeneca Announce Positive Phase III SANOVO Trial in NSCLCPositive clinical trial outcome for a combination therapy involving a key marketed product (Tagrisso) and a partnered asset (Savolitinib), potentially expanding market opportunities and reinforcing Tagrisso's franchise.Bullish1-3m0.60
    2026-08-31HUTCHMED and AstraZeneca report positive Phase III trial for Orpathys plus TagrissoPositive clinical trial outcome for a combination therapy involving a key marketed product (Tagrisso) and a partnered asset (Orpathys), expanding market potential.Bullish3-12m0.60
    2026-08-31HUTCHMED and AstraZeneca report positive Phase III SANOVO lung cancer trial dataDirect impact from successful clinical trial results for a combination therapy involving one of its blockbuster drugs (osimertinib) and a partner's drug (savolitinib), expanding its market potential.Bullish3-12m0.70
    2026-08-31HUTCHMED and AstraZeneca Report Positive Phase III SANOVO Trial in ChinaDirect impact from successful clinical trial results for a co-developed drug, contributing to pipeline strength and potential future revenue streams.Bullish1-3m0.60
    2026-08-28China NMPA grants conditional approval for HUTCHMED's ATLED in oncologyPotential competitive pressure or partnership opportunities in the FGFR inhibitor space within China.watch3-12m0.30
    2026-08-28HUTCHMED Receives NMPA Conditional Approval for ATLED in ChinaPotential competitive pressure in the oncology market, particularly for FGFR2-altered ICC, or potential partnership implications.watch3-12m0.20

    Continue this research

    Build your AstraZeneca PLC investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.

    This ledger is regenerated from Market Ontology's public event pipeline. View the AZN entity page →

    Research AstraZeneca PLC · $399/mo